Abstract
BackgroundCitation bias occurs when positive trials involving a medical intervention receive more citations than neutral or negative trials of similar quality. Several large clinical trials have studied the use of thrombolytic agents for the treatment of acute ischemic stroke with differing results, thereby presenting an opportunity to assess these trials for evidence of citation bias. We compared citation rates among positive, neutral, and negative trials of alteplase (tPA) and other thrombolytic agents for stroke.MethodsWe used a 2014 Cochrane Review of thrombolytic therapy for the treatment of acute stroke to identify non-pilot, English-language stroke trials published in MEDLINE-indexed journals comparing thrombolytic therapy with control. We classified trials as positive if there was a statistically significant primary outcome difference favoring the intervention, neutral if there was no difference in primary outcome, or negative for a significant primary outcome difference favoring the control group. Trials were also considered negative if safety concerns supported stopping the trial early. Using Scopus, we collected citation counts through 2015 and compared citation rates according to trial outcomes.ResultsEight tPA trials met inclusion criteria: two were positive, four were neutral, and two were negative. The two positive trials received 9080 total citations, the four neutral trials received 4847 citations, and the two negative trials received 1096 citations. The mean annual per-trial citation rates were 333 citations per year for positive trials, 96 citations per year for neutral trials, and 35 citations per year for negative trials. Trials involving other thrombolytic agents were not cited as often, though as with tPA, positive trials were cited more frequently than neutral or negative trials.ConclusionsPositive trials of tPA for ischemic stroke are cited approximately three times as often as neutral trials, and nearly 10 times as often as negative trials, indicating the presence of substantial citation bias.Electronic supplementary materialThe online version of this article (doi:10.1186/s13063-016-1595-7) contains supplementary material, which is available to authorized users.
Highlights
Citation bias occurs when positive trials involving a medical intervention receive more citations than neutral or negative trials of similar quality
Because citation bias often results in the disproportionate citation of studies with statistically significant or “positive” results, it may result in a distortion of Misemer et al Trials (2016) 17:473 the perceived efficacy of medical treatments within the published scientific literature [6]
Main results The eight included trials of alteplase (tPA) trials consisted of two reporting a statistically significant benefit for the primary outcome [11, 12], four that completed enrollment but showed no benefit based on the primary outcome [13,14,15,16], and two that were stopped early due to Safety Committee concerns [17, 18]
Summary
Citation bias occurs when positive trials involving a medical intervention receive more citations than neutral or negative trials of similar quality. Prior efforts to characterize the presence of citation bias in the medical literature have observed this form of bias among studies of therapeutic interventions, with approximately twice as many citations for studies with statistically significant results [7], but not among a broader range of study types [8]. Goals of this investigation We assessed for evidence of citation bias among clinical trials of tPA and other thrombolytic agents in the treatment of acute ischemic stroke
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
